Community Practice

New and old non-opioid pain management solutions. 

Currently under DEA review.

Tips for identifying patients with diabetes who need more direction and help.

Noteworthy diabetes management products and updates making waves this year.

Consumers should stop use and report any adverse events.

How to help manage two of the most common autoimmune diseases.

One child has already died from complications.

The drug comes at a time when antibiotic resistance worries are high. Here’s why it matters.

New CGM eliminates fingersticks, introduces new data presentation.

Afamelanotide released through subcutaneous implant.

After last year’s drawn-out flu season, the CDC weighs in on what to expect in 2019-2020

Pharmacies are making the most of tech from automation to big data.

Also indciated to control bleeding and perioperative management.

Why is pharmacy work so stressful, and how can pharmacists take care of that stress?

Injection for leading cause of severe vision loss and legal blindness.

First new treatment of its kind in over 20 years.

More doctors referring patients to pharmacies for shots.

Characterized by severe abdominal pain.

Currently only approved for men and transgender women; future trials expected.

Whether marijuana use increases COPD susceptibility remains uncertain.

Only 50% of COPD patients are estimated to be vaccinated.

The DEA had access to information about where opioids were being sold, but didn’t act on it. Why?

Biosimilars may need more time to devleop in the market.

For granulomatosis with microscopic polyangiitis in children.

Now approved for risk reductions in patients with type 2 diabetes mellitus.